Cargando…
Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice
Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder (LSD) characterized by severe central nervous system (CNS) degeneration. The disease is caused by mutations in the SGSH gene coding for the lysosomal enzyme sulfamidase. Sulfamidase deficiency leads to accumulation of heparan...
Autores principales: | Gustavsson, Susanne, Ohlin Sjöström, Elisabet, Tjernberg, Agneta, Janson, Juliette, Westermark, Ulrica, Andersson, Tommy, Makower, Åsa, Arnelöf, Erik, Andersson, Gudrun, Svartengren, Jan, Ekholm, Carina, Svensson Gelius, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737345/ https://www.ncbi.nlm.nih.gov/pubmed/31528541 http://dx.doi.org/10.1016/j.ymgmr.2019.100510 |
Ejemplares similares
-
Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2019) -
Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014) -
Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018) -
Distribution of Heparan Sulfate Oligosaccharides in Murine Mucopolysaccharidosis Type IIIA
por: Mason, Kerryn, et al.
Publicado: (2014) -
Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome
por: Hendrikse, Natalie M., et al.
Publicado: (2021)